S&P 500   4,073.82 (+1.64%)
DOW   32,575.13 (+1.09%)
QQQ   304.49 (+2.03%)
AAPL   148.71 (+2.18%)
MSFT   264.76 (+1.25%)
FB   201.75 (+0.85%)
GOOGL   2,319.14 (+1.32%)
AMZN   2,264.42 (+2.18%)
TSLA   755.29 (+4.27%)
NVDA   179.95 (+4.23%)
BABA   90.60 (+4.76%)
NIO   16.56 (+13.81%)
AMD   102.57 (+8.84%)
CGC   5.91 (+3.14%)
MU   73.89 (+4.85%)
T   20.45 (+0.84%)
GE   76.59 (+2.63%)
F   13.41 (+2.76%)
DIS   107.50 (+2.21%)
AMC   12.39 (+5.81%)
PFE   51.41 (+1.46%)
PYPL   78.88 (+1.58%)
NFLX   188.80 (+1.23%)
S&P 500   4,073.82 (+1.64%)
DOW   32,575.13 (+1.09%)
QQQ   304.49 (+2.03%)
AAPL   148.71 (+2.18%)
MSFT   264.76 (+1.25%)
FB   201.75 (+0.85%)
GOOGL   2,319.14 (+1.32%)
AMZN   2,264.42 (+2.18%)
TSLA   755.29 (+4.27%)
NVDA   179.95 (+4.23%)
BABA   90.60 (+4.76%)
NIO   16.56 (+13.81%)
AMD   102.57 (+8.84%)
CGC   5.91 (+3.14%)
MU   73.89 (+4.85%)
T   20.45 (+0.84%)
GE   76.59 (+2.63%)
F   13.41 (+2.76%)
DIS   107.50 (+2.21%)
AMC   12.39 (+5.81%)
PFE   51.41 (+1.46%)
PYPL   78.88 (+1.58%)
NFLX   188.80 (+1.23%)
S&P 500   4,073.82 (+1.64%)
DOW   32,575.13 (+1.09%)
QQQ   304.49 (+2.03%)
AAPL   148.71 (+2.18%)
MSFT   264.76 (+1.25%)
FB   201.75 (+0.85%)
GOOGL   2,319.14 (+1.32%)
AMZN   2,264.42 (+2.18%)
TSLA   755.29 (+4.27%)
NVDA   179.95 (+4.23%)
BABA   90.60 (+4.76%)
NIO   16.56 (+13.81%)
AMD   102.57 (+8.84%)
CGC   5.91 (+3.14%)
MU   73.89 (+4.85%)
T   20.45 (+0.84%)
GE   76.59 (+2.63%)
F   13.41 (+2.76%)
DIS   107.50 (+2.21%)
AMC   12.39 (+5.81%)
PFE   51.41 (+1.46%)
PYPL   78.88 (+1.58%)
NFLX   188.80 (+1.23%)
S&P 500   4,073.82 (+1.64%)
DOW   32,575.13 (+1.09%)
QQQ   304.49 (+2.03%)
AAPL   148.71 (+2.18%)
MSFT   264.76 (+1.25%)
FB   201.75 (+0.85%)
GOOGL   2,319.14 (+1.32%)
AMZN   2,264.42 (+2.18%)
TSLA   755.29 (+4.27%)
NVDA   179.95 (+4.23%)
BABA   90.60 (+4.76%)
NIO   16.56 (+13.81%)
AMD   102.57 (+8.84%)
CGC   5.91 (+3.14%)
MU   73.89 (+4.85%)
T   20.45 (+0.84%)
GE   76.59 (+2.63%)
F   13.41 (+2.76%)
DIS   107.50 (+2.21%)
AMC   12.39 (+5.81%)
PFE   51.41 (+1.46%)
PYPL   78.88 (+1.58%)
NFLX   188.80 (+1.23%)
NASDAQ:NTLA

Intellia Therapeutics (NTLA) Stock Forecast, Price & News

$48.13
+2.17 (+4.72%)
(As of 05/17/2022 01:39 PM ET)
Add
Compare
Today's Range
$45.57
$48.54
50-Day Range
$39.94
$76.23
52-Week Range
$38.85
$202.73
Volume
13,189 shs
Average Volume
1.22 million shs
Market Capitalization
$3.65 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.14
30 days | 90 days | 365 days | Advanced Chart
Receive NTLA News and Ratings via Email

Sign-up to receive the latest news and ratings for Intellia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Intellia Therapeutics logo

About Intellia Therapeutics

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NTLA
Fax
N/A
Employees
485
Year Founded
N/A

Sales & Book Value

Annual Sales
$33.05 million
Book Value
$14.15 per share

Profitability

Net Income
$-267.89 million
Net Margins
-973.48%
Pretax Margin
-810.49%

Debt

Price-To-Earnings

Miscellaneous

Free Float
72,896,000
Market Cap
$3.65 billion
Optionable
Optionable

Company Calendar

Last Earnings
5/05/2022
Today
5/17/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.16 out of 5 stars

Medical Sector

419th out of 1,423 stocks

Diagnostic Substances Industry

7th out of 27 stocks

Analyst Opinion: 4.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -













Intellia Therapeutics (NASDAQ:NTLA) Frequently Asked Questions

Is Intellia Therapeutics a buy right now?

21 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last twelve months. There are currently 2 hold ratings and 19 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Intellia Therapeutics stock.
View analyst ratings for Intellia Therapeutics
or view top-rated stocks.

When is Intellia Therapeutics' next earnings date?

Intellia Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Intellia Therapeutics
.

How were Intellia Therapeutics' earnings last quarter?

Intellia Therapeutics, Inc. (NASDAQ:NTLA) posted its earnings results on Thursday, May, 5th. The company reported ($1.96) EPS for the quarter, missing analysts' consensus estimates of ($1.11) by $0.85. The business had revenue of $11.30 million for the quarter, compared to analyst estimates of $8.57 million. Intellia Therapeutics had a negative trailing twelve-month return on equity of 41.85% and a negative net margin of 973.48%. The business's quarterly revenue was up 73.8% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.69) earnings per share.
View Intellia Therapeutics' earnings history
.

What price target have analysts set for NTLA?

21 brokerages have issued 12-month price objectives for Intellia Therapeutics' shares. Their forecasts range from $83.00 to $252.00. On average, they expect Intellia Therapeutics' share price to reach $143.50 in the next twelve months. This suggests a possible upside of 198.2% from the stock's current price.
View analysts' price targets for Intellia Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Intellia Therapeutics' key executives?
Intellia Therapeutics' management team includes the following people:
What is John Leonard, M.D.'s approval rating as Intellia Therapeutics' CEO?

12 employees have rated Intellia Therapeutics CEO John Leonard, M.D. on Glassdoor.com. John Leonard, M.D. has an approval rating of 73% among Intellia Therapeutics' employees.

What other stocks do shareholders of Intellia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intellia Therapeutics investors own include Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Alibaba Group (BABA), Square (SQ), Micron Technology (MU), Advanced Micro Devices (AMD), Intel (INTC), Invitae (NVTA) and Cisco Systems (CSCO).

When did Intellia Therapeutics IPO?

(NTLA) raised $85 million in an IPO on Friday, May 6th 2016. The company issued 5,000,000 shares at $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Intellia Therapeutics' stock symbol?

Intellia Therapeutics trades on the NASDAQ under the ticker symbol "NTLA."

Who are Intellia Therapeutics' major shareholders?

Intellia Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (12.03%), Vanguard Group Inc. (8.43%), BlackRock Inc. (7.38%), Sumitomo Mitsui Trust Holdings Inc. (3.85%), Nikko Asset Management Americas Inc. (3.85%) and Viking Global Investors LP (3.25%). Company insiders that own Intellia Therapeutics stock include Andrew Schiermeier, Caroline Dorsa, David Lebwohl, Glenn Goddard, Jean Francois Formela, John F Crowley, John M Leonard, John M Leonard, Jose E Rivera, Jose E Rivera, Laura Sepp-Lorenzino and Perry A Karsen.
View institutional ownership trends for Intellia Therapeutics
.

Which institutional investors are selling Intellia Therapeutics stock?

NTLA stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Lord Abbett & CO. LLC, Goldman Sachs Group Inc., Dimensional Fund Advisors LP, Invesco Ltd., Chevy Chase Trust Holdings Inc., Prudential Financial Inc., and Vanguard Group Inc.. Company insiders that have sold Intellia Therapeutics company stock in the last year include David Lebwohl, Glenn Goddard, Jean Francois Formela, John F Crowley, John M Leonard, and Laura Sepp-Lorenzino.
View insider buying and selling activity for Intellia Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Intellia Therapeutics stock?

NTLA stock was purchased by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Viking Global Investors LP, State Street Corp, Citigroup Inc., Polar Capital Holdings Plc, Frazier Life Sciences Management L.P., Wellington Management Group LLP, and Nikko Asset Management Americas Inc..
View insider buying and selling activity for Intellia Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Intellia Therapeutics?

Shares of NTLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intellia Therapeutics' stock price today?

One share of NTLA stock can currently be purchased for approximately $48.13.

How much money does Intellia Therapeutics make?

Intellia Therapeutics has a market capitalization of $3.65 billion and generates $33.05 million in revenue each year. The company earns $-267.89 million in net income (profit) each year or ($5.030010) on an earnings per share basis.

How many employees does Intellia Therapeutics have?

Intellia Therapeutics employs 485 workers across the globe.

What is Intellia Therapeutics' official website?

The official website for Intellia Therapeutics is www.intelliatx.com.

How can I contact Intellia Therapeutics?

Intellia Therapeutics' mailing address is 40 Erie Street Suite 130, Cambridge MA, 02139. The company can be reached via phone at (857) 285-6200 or via email at [email protected].

This page was last updated on 5/17/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.